Unlocking Energy: How Oxygen Levels Can Predict Health in Barth Syndrome
"Discover the groundbreaking research on oxygen uptake (VO2peak) in Barth syndrome, offering new hope for monitoring and improving the lives of those affected."
Barth syndrome (BTHS) is a rare, genetic condition that primarily affects males. It's characterized by a range of health challenges, including heart problems, muscle weakness, and developmental delays. Because it's so rare—affecting approximately one in 300,000 births—understanding how to best monitor and manage the condition is an ongoing effort.
One key area of focus is how well the body uses oxygen during exercise. This is measured by what's known as peak oxygen uptake, or VO2peak. Reduced VO2peak levels have been observed in individuals with BTHS; however, little is known about how VO2peak changes over time, especially from childhood through adulthood.
Now, new research is shedding light on this important aspect of Barth syndrome. A recent study published in PLOS One investigates VO2peak levels across different age groups, providing valuable insights into the stability and predictability of this measure. This article dives into the details of this study, explaining what it means for individuals with BTHS and their families.
Establishing Oxygen Uptake as a Key Marker
Barth syndrome is an ultra-rare, X-linked recessive disorder characterized by cardio-skeletal myopathy, exercise intolerance, and growth delay. Clinical reviews likewise describe cardiomyopathy, skeletal myopathy, neutropenia, and growth abnormalities as central features of the condition. Research published in 2018 examined peak oxygen uptake (VO2peak) across childhood, adolescence, and young adulthood using cross-sectional and longitudinal data, addressing an earlier gap in understanding how exercise capacity changes over time.
VO2peak: A Stable Indicator Across the Lifespan?
The PLOS One study aimed to track VO2peak from childhood to young adulthood in individuals with BTHS. Researchers used both cross-sectional and longitudinal data, meaning they looked at different age groups at one point in time and also followed individuals over several years. This comprehensive approach provided a more complete picture of how VO2peak evolves.
- VO2peak, when adjusted for body weight and fat-free mass, remained relatively stable across all age groups (children, adolescents, and young adults).
- Longitudinal data showed that VO2peak did not significantly change over a mean time of approximately five years in late adolescents and young adults.
- A model that included both cardiac (heart-related) and skeletal muscle variables best predicted VO2peak.
Measuring Exercise Capacity and Mitochondrial Energetics
A study titled "Cardiac Transplantation Does Not Improve Exercise Tolerance, Muscle Mass, or Substrate Metabolism in Barth Syndrome" used graded exercise testing, echocardiography, body-composition analysis, and clinical metabolism studies. Its methods included phosphorus-31 magnetic resonance spectroscopy (31 P-MRS) to assess mitochondrial energetics. These measurements place oxygen-based exercise capacity within a broader evaluation of cardiac function, body composition, and muscle energy metabolism.
Why Absolute VO2peak Can Mislead
In the Barth syndrome VO2peak study, absolute VO2peak in liters per minute and peak work rate increased significantly with advancing age group. However, VO2peak did not differ between age groups when expressed relative to body weight, fat-free mass, or percent of predicted VO2max. The researchers therefore reported short- and long-term stability in VO2peak relative to body weight and fat-free mass, while noting some individual variability.
What This Means for Individuals with Barth Syndrome
The stability of VO2peak as an indicator has important implications for clinical trials and treatment strategies. Because it remains consistent over time, VO2peak can be used to accurately assess the impact of new therapies aimed at improving cardiac and skeletal muscle function. This could lead to more effective interventions and improved quality of life for those living with BTHS.
Building Larger Longitudinal Evidence
A May 3, 2026 report notes that formal analyses of survival and clinical progression in Barth syndrome remain limited. The Barth Syndrome Foundation has maintained an intake database of 502 people, representing more than 80% of the known global population, and a patient-inputted registry containing 162 individuals with up to 11 years of longitudinal outcome data. These resources could support more detailed analyses of long-term disease progression.